Human tumor antigens recognized by T-cells

Immunologic Research

Volumn 16, Issue 4, 1997, Pages 313-339

  Kawakami, Yutaka ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Immunotherapy; T cells; Tolerance; Tumor antigens

Indexed keywords

EPITOPE; TUMOR ANTIGEN; VIRUS PROTEIN;

ACTIVE IMMUNIZATION; ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; HUMAN; MELANOMA; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR MODEL;

EID: 0031439719     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02786397     Document Type: Review

References (137)

1. Kawakami Y, Robbins PF, Wang RF, Rosenberg SA: Identification of melanoma antigens recognized by T lymphocytes and their use in the immunotherapy of cancer; in Devita VT, Hellman S, Rosenberg SA (eds.): Principle and Practice of Oncology, Opdate. Philadelphia, Lippincott-Raven, pp 1-20.
2. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr- transformed B cells. Int J Cancer 1994;58:69-79.
3. + T lymphocytes against human melanoma: evidence for a shared melanoma antigen presented by HLA-DR15. J Immunol 1995;154:772-779.
4. Darrow TL, Slingluff CL, Seigler HF: The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytutoxic T lymphocytes: evidence for shared tumor antigens. J Immunol 1989;142:3329-3335.
5. Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA: Shared human melanoma antigens. Recognition by tumor infiltrating lymphocytes in HLA-A2.1 transfected melanomas. J Immunol 1992;148:638-643.
6. Anichini A, Mortarini R, Maccalli C, Squarcina P, Fleischhauer K, Mascheroni L, Parmiani G: Cytotoxic T-cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol 1996;156:208-217.
7. Disis M, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, Cheever MA: Existent T-cell and antibody immunity to Her2/neu protein in poatients with breast acner. Cancer Res 1994;54:16-20.
8. Crawfold LV, Pim DC, Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982;30:403-408.
9. Kawakami Y, Nishimura I, Restifo NP, Topalian SL, O'Neil BH, Shilyansky J, Yannelli JR, Rosenberg SA: T-cell recognition of human melanoma antigens. J Immunother 1993;14:88-93.
10. Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethë B, Coulie P, Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178: 489-495.
11. Robbins PF, El-Gamil M, Kawakami Y, Stevens E, Yannelli J, Rosenberg SA: Recognition of tyrosinase by tumor infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Research 1994;54: 3124-3126.
12. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA: Identification of a Human Melanoma Antigen Recognized by Tumor Infiltrating Lymphocytes Associated with in vivo Tumor Rejection. Proc Natl Acad Sci USA 1994;91:6458-6462.
13. Bakker ABH, Schreurs MWJ, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG: Melanocyte lineage-specific antigen gp100 is recognized by melanocyte-derived tumor-infiltrating lymphocytes. J Exp Med 1994; 179:1005-1009.
14. Cox AL, Skipper J, Cehn Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL: Identification of a peptide recognized by five melanoma-specific human cytotoxic T-cell lines. Science 1994;264:716-719.
15. Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, Rosenberg SA: Human CD4+T-cells specificaly recognize a shared melanoma-associated antigen encoded by the tyrosinasegene. Proc Natl Acad Sci USA 1994;91:9461-9465.
16. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA: Identification of TRP2 as a human tumor antigen recognizd by cytotoxic T lymphocytes. J Exp Med 1996;184:2207-2216.
17. Celis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chestnut RW, Grey HM, Sette A, Serra HM: Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994;91:2105-2109.
18. Gaugler B, Van Den Eynde B, Van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179:921-930.
19. Ropke M, Hald J, Guldberg P, Zeuthen J, Norgaard L, Fugger L, Svejgaard A, Van Der Burg S, Numan HW, Melief CJM, Claesson MH: Spontaneous human squamous cell carcinoma are killed by a human cytotoxic T lymphocyte clone recognizing a wild type p53 derived peptide. Proc Natl Acad Sci USA 1996;93:14,704-14,707.
20. + T ells recognize a peptide corresponding to a common mutation (13Gly-Asp). Int J Cancer 1994;56:40-45.
21. Geede-Dahl T, Spurkland AL, FossumB, WittinghoferA, Thorsby E, GaudernackG:T-cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA. Eur J Immunol 1994;24:410-414.
22. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton M, Schlom J: Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombiant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87:982-990.
23. Correale P, Walmsley K, Nierod C, Zaremba S, Zhu M, Schlom J, Tsang K: In vitor generation of human cytotoxic T lymphocytes specific for peptide derived from prostate specific antigen. J Natl Cancer Inst 1997;89:293-300.
24. Ressing ME, Sette A, Brandt RMP, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJM, Kast WM: Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995;154: 5934-5943.
25. Houbiers JGA, Nijman HW, van der Burg SH, Drijfhout JW, Kenemans P, van de Velde CJH, Brand A, Momburg F, Kast WM, Melief CJM: In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993; 23:2072-2077.
26. Elas AV, Nijman HW, Van der Minne CE, Mourer JS, Kast WM, Melief CJM, Schrier PI: Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21 RAS peptide presented by HLA-A2010. Int J Cancer 1995;61:389-396.
27. Castelli C, Storkus WJ, Maeurer MJ, Martin DM, Huang C, Pramanik BN, Nagabhushan TL, Parmiani G, Lotze MT: Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995;181:363-368.
28. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, DePlaen E, Van Den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-1647.
29. Kawakami Y, Eliyahu S, Delgaldo CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA: Cloning of the Gene Coding for a Shared Human Melanoma Antigen Recognized by Autologous T-cells Infiltrating into Tumor. Proc Natl Acad Sci USA 1994;91:3515-3519.
30. Gaugler B, Brouwenstijn N, Vantomme V, Szikora JP, Van der Spek CW, Patard JJ, Boon T, Schrier P, Van den Eynde BJ: A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics 1996;44:323-330.
31. Brandle D, Brasseur F, Weynants P, Boon T, Van den Eynde BJ: A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med 1996; 183:2501-2508.
32. Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G: Melanoma cells and normal melanocy tes share antigens recognized by HLA-A2 restricted cytotoxic T-cell clones from melanoma patients. J Exp Med 1993;177: 989-998.
33. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-495.
34. Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer Zum Buschenfelde KH, Boon T: Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994;24:759-764.
35. Kang XQ, Kawakami Y, Sakaguchi K, El-Gamil M, Wang RF, Yannelli JR, Appella E, Rosenberg SA, Robbins PF: Identification of a tyrosinase epitope reocognized by HLA-A24 restricted tumor-infiltrating lymphocytes. J Immunol 1995;155:1343-1348.
36. Brichard VG, Herman J, Van Pel A, Wildmann C, Gaugler B, Wolfel T, Boon T, Lethe B: A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol 1996;26:224-230.
37. + T-cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 1996;183:1965-1971.
38. Skipper JCA, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabanowitz J, Wolfel T, Slingluff CL Jr, Boon T, Hunt DF, Engelhard VH: An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996;183:527-534.
39. Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A: Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996;66:470-476.
40. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, Mattel S, De Plaen ED, Lurquin C, Szikora JP, Reauld JC, Boon T: A new gene coding for adifferentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994; 180:35-42.
41. Kawakami Y, Battles JK, Kobayashi T, Ennis W, Wang X, Tupesis JP, Marincola FM, Robbins PF, Hearing VJ, Gonda MA, Rosenberg SA: Production of recombinant MART-1 proteins and specific anti-MART-1 polyclonal and monoclonal antibodies: Use in the characterization of the human melanoma antigen MART-1. J Immunol Methods 1996;202:13-25.
42. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JB, Appella E, Rosenberg SA: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med 1994;180: 347-352.
43. Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E, Rosenberg SA: Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-2265.
44. Kawakami Y, Rosenberg SA: T-cell recognition of self peptides as tumor rejection antigens. Immunol Res 1995;15:179-190.
45. Loftus DJ, Castelli C, Clay TM, Squarcina P, Marincola FM, Nichimura MI, Parmiani G, Appella E, Rivoltini L: Identification of epitope mimics recognized by CTL reactive to the melanoma/ melanocyte-derived peptide MART-127-35. J Exp Med 1996;184:647-657.
46. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM: Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37-44.
47. Adema GJ, de Boer AJ, van't Hullenaa rR, Denijn M, Ruiter DJ, Vogel AM, Figdor CG: Melanocyte lineage-specific antigens recognized by monoclonal antibodies NK1-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. Am J Pathol 1993;143:1579-1585.
48. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang XQ, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg S A: Recognition of multiple epitopes in the human melanoma antigen gp100 associated with in vivo tumor regression. J Immunol 1995;154:3961-3968.
49. Bakker A, Schreurs M, Tafazzu G, de Boer A, Kawakami Y, Adema G, Figdor C: Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int J Cancer 1995;62:97-102.
50. Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A, Celis E: Induction of subdominant CTL epitopes of the gp100 melanoma associated tumor antigen by primary in vitro immuni/ation with peptide pulsed dendritic cells. J Immunol 1997;158:1796-1802.
51. Skipper JCA, Kittlesen DJ, Hendrickson RC, Deacon DD, Harthun NL, Wagner SN, Hunt DF, Engelhard VH, Slingluff CL: Shared epitopes for HLA-A3 restricted melanoma reactive human CTL include a naturally processed epitope from Pmel-17/ gp100. J Immunol 1996;157: 5027-5033.
52. Robbins PF, El-Gamil M, Li YF, Fitzgerald E, Kawakami Y, Rosenberg SA: The intronic region of an imcompletely-spliced gp100 gene transcript encodes an epitope recognized by melanoma reactive tumor infiltrating lymphocytes. J Immunol 1997;159:303-308.
53. Mattes MJ, Thomson TM, Old LJ, Old KO: A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum. Int J Cancer 1995;32:717-721.
54. Wang RF, Robbins PF, Kawakami Y, Rang XQ, Rosenberg SA: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 1995;181:799-804.
55. Topalian SL, Muul LM, Solomon D, Rosenberg SA: Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Meth 1987; 102:127-141.
56. Hara I, Takechi Y, Houghton AN: Implicating a role for immune recognition of self in tumor rejection: passive immunization against the Brown locus protein. J Exp Med 1995;182:1609-1614.
57. Wang RF, Parkhurst M, Kawakami Y, Robbins PF, Rosenberg SA: Ulilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 1996;183: 1131-1140.
58. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA: Identification of TRP2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996;184:2207-2216.
59. Bloom MB, Lalley DP, Robbins PF, Li Y, El-Gamil M, Rosenberg SA, Yang JC: Identification of TRP2 as a tumor rejection antigen r the B16 melanoma. J Exp Med 1997;185:453-459.
60. Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, CoulieP, Boon T, Van der Bruggen P: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995; 2:167-175.
61. Van Den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182:689-698.
62. de Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T: The actvation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 1996;93:7149-7153.
63. Traversari C, Van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-1457.
64. Van der Bruggen P, Szikora JP, Boel P, Wildmann C, Somville M, Sensi M, Boon T: Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing Cw 1601. Eur J Immunol 1994;24:2134-2140.
65. Van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, de Smet C, Traversari C, Townsend A, Boon T: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994; 24:3038-3043.
66. Herman J, Van der Bruggen P, Luescher IF, Mandruzzato S, Romero P, Thonnard J, Fleischhauer K, Boon T, Coulie PG: A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induced cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics 1996; 43:377-383.
67. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Prfiri E, Polakis P: Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997;275:1790-1792.
68. Brash DE, Rudolph JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J: A role of sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991; 88:10,124-10,128.
69. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA: A mutated ß-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185-1192.
70. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer Zum Buschenfelde KH, Beach D: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-1284.
71. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, Boon T: A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 1995;92:7976-7980.
72. Guilloux Y, Lucas S, Brichard VG, VanPel A, Viret C, De Plaen E, Brasseur F, Lethe B, Jotereau F, Boon T: A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanoma is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med 1996;183:1173-1183.
73. Robbins PF, El-Gamil M, LiY F, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA: Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24 restricted tumorinfiltrating lymphocytes. J Immunol 1995;154:5944-5950.
74. Ikeda H, Lethe B, Lehmann F, Van Baren N, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG: Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997;6:199-208.
75. Yoshino I, Peopes GE, Goedegebuure PS, Maziarz R, Eberlein TJ: Association of Her2/ neu expression with sensitivity to tumor specific CTL in human ovarian cacner. J Immunol 1994; 152:2393-2400.
76. Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ: Tumor specific and HLA-A2 restricted cytolysis by tumor associated lymphocytes in human metastatic breast cancer. J Immunol 1995;155:4486-4491.
77. Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, DiMaio JM, Lyerly HK, Gazdar AF, Eberlein TJ: Her2/neu derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 1994;54:3387-3390.
78. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995;92:432-436.
79. Fisk B, Blevins TL, Wharton J, Ioannides C: Identification of an immunodominant peptide of HER2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocytes lines. J Exp Med 1995;181:2109-2117.
80. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA: Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997;185:833-841.
81. Fossum B, Breivik J, Meling GI, Gedde-Dahl T, Hansen T, Knutsen I, Rognum T, Thorsby E, Gaudemack G: A K-ras 13Gly-Asp mutation is recognized by HLA-DQ7 restricted T-cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harbouring this mutation? Int J Cancer 1994;58:506-511.
82. Gedde-Dahl T, Spurkland A, Eriksen JA, Thorsby E, Gaudernack G: Memory T-cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-Leu61). Int Immunol 1992;4:1331-1337.
83. Forssum B, Olsen AC, Thorsb yE, Gaudernack G: CD8+ T-cells om a patient with colon carcinma, specific fror a mutant p21 ras derived peptide (Gly13-Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol Immunother 1995;40:165-172.
84. Barnd DL, Lan M, Metzgar RS, Finn OJ: Specific MHC unrestricted recognition of tumor associated mucins by human cytotoxic T-cells. Proc Natl Acad Sci USA 1989;86:7159-7163.
85. Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K, Yachi A: Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from multiple myeloma patient. J Immunol 1994;153: 2102-2109.
86. Domenech N, Henderson RA, Finn OJ: Identification of an HLA-A11 restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 1995;155:4766-4774.
87. Goydos JS, Elder E, Whiteside T, Finn OJ, Lotze MT: A phase I trial of a synthetic mucin peptide vaccine: induction of specific immune reactiveity in patients with adenocarcinoma. J Surgical Res 1996; 63:298-304.
88. Kast WM, Brandt MP, Drijfhout JW, Melief CJM: Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus Type16 E6 and E7 proteins identified by using the processing defective human cell line T2. J Immunother 1993;14:115-120.
89. Kast WM, Brandt RMP, Sidney J, Drijfhout JW, Kubo RT, Grey HM, Melief CJM, Sette A: Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994;152: 3904-3912.
90. Alexander M, Salgaller ML, Celis E, Sette A, Barnes WA, Rosenberg SA, Steller MA: Generation of tumor specific cytolytic T-lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic HPV-16 E7 epitope. Am J Obst Gyn 1996; 175:1586-1593.
91. Ressing ME, van Driel WJ, Celis E, Sette A, Brandt RMP, Hartman M, Anholts JDH, SchreuderG M T, ter Harmsel WB, Fleuren GJ, Trimbos BJ, Kast WM, Melief CJM: Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res 1996;56:582-588.
92. Stellaer M, Schiller JT: Human papillomavirus immunology and vaccine prospects. Monogr Natl Cancer Inst 1996;21:145-148.
93. Gavioli R, De Campos-Lima PO, Kurilla MG, Kieff E, Klein G, MasucciMG:Recognition of the Epstein-Barr virus encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11 restricted cytotoxic T lymphocytes: Implications fro down regulation of HLA-A11 in Burkitt lymphoma. Proc Natl Acad Sci USA 1992;89:5862-5866.
94. Murray R, Kurilla M, Brooks J, Thgomas W, Rowe M, Kieffe E, Rikson A: Identification of target antigens for the human cytotoxic T-cell response to Epstein-Barr virus (EBV): Implication for the immune control of EBV-positive malignancy. J Exp Med 1992; 176:157-168.
95. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-58.
96. Haas GG, D'Cruz OJ, De Bault LE: Distribution of human leukocyte antigen-ABC and -D/DR antigens in the unfixed human testis. Am J Reprod Immunol Microbiol 1988;18:47-51.
97. Meadows L, Wang W, den Haan JMM, Drijfhout JW, Shabanowitz J, Pierce R, Aguinik AI, Bishop CE, Hunt DF, Goulm yE, Engelhard VH: The HLA-A*0201 restircted H-Y antigen contains a posttrans-lationally modified cystein that significantly affects T-cell recognition. Immunity 1997;6:273-281.
98. Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magarian-Blander J, Barratt-Boyes SM: MUC-1 epithelial tumor mucin based immunity and cancer vaccines. Immunological Reviews 1997; 145:61-89.
99. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ: Humoral immunity against a tamdem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994;54:2856-2860.
100. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of ptients with metastatic melanojma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1995;86:1159-1166.
101. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, WhiteDE: Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N Engl J Med 1988;319:1676-1680.
102. Rosenberg SA, White DE: Vitiligo in patients with melanoma: Normal tissue antigens can be target for cancer immunotherapy. J Immunother 1996;19:81-84.
103. Rosenberg SA: Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst 1996;88:1635-1644.
104. Zhai Y, Yang JC, Kawakami Y, Spiess P, Wadsworth SC, Cardoza LM, Couture LA, Smith AE, Rosenberg SA: Antigen-specific tumor vaccines: Development and characterization of recombinant adenoviruses encoding MART-1 or gp100 for cancer therapy. J Immunol 1996;156:700-710.
105. Van Pel A, van der Brugen P, Coulie PG, Brichard VG, Lethe B, van der Eynde B, Uyttenhove C, Renauld JC, BoonB:Genes coding for tumor antigens recognized by cytolytic T lymphocytes, Immunol Rev 1995;145:229-250.
106. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, ParmianiG, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, Canon J-L, LaurentC, Naeyaert J M, Plagne R, Deraemaeker R, Knuth A, Jager E, Brasseur F, Herman J, Coulie PG, Boon T: Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1996;63:883-885.
107. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJA, Levesque MA, Roagna R, Ponzone R, Sismondi P: Prostate specific antigen is a new favorable prognistic indicator for woman with breast cancer. Cancer Res 1995; 55:2104-2110.
108. Jerome KR, Kirk AD, Pecher G, Fergusson WW, Finn OJ: A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis. Cancer Immunol Immunother 1997;43:355-2360.
109. Wiedenfeld EA, Fernandez-Vina M, Berzofsky JA, Carbone DP: Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A-0201 peptide consensus motif. Cancer Res 1994;54:1175-1177.
110. Rosenberg SA: The immunotherapy and gene therapy of cancer. J Clin Oncol 1992;10:180-199.
111. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T-cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
112. Nair SK, Boczkowski D, Snyder D, Gilboa E: Antigen presenting cells pulsed with unfractionated tumor derived peptides are potent tumor vaccines. Eur J Immunol 1997;27:589-597.
113. NairS K, Snyder D, Rouse BT, Gilboa E: Regression of tumors in mice vaccinated with professional antigen presenting cells pulsed with tumor extracts. Int J Cancer 1997;70:706-715.
114. Boczkowski D, Nair SK, Snyder D, Gilboa E: Dendritic cells pulsed with RNA are potent antigen presenting cells in vitro and in vivo. J Exp Med 1996;184:465-472.
115. Udono H, Srivastava P: Comparison of tumor specific immunogenicities of stress-induced proteins gp96, Hsp90, and Hsp80. J Immunol 1994;152:5398-5403.
116. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA: Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996;56:4749-4757.
117. Walte EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe K S, Thomas ED, Riddell SR: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038-1044.
118. Irvine KR, Restifo NP: The next wave of recombinant and synthetic anticancer vaccines. Semin Cancer Biol 1995;6:337-347.
119. Mayordomo J, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze M, Storkus WJ, Appella E, DeLeo AB: Therapy of murine tumors with wild type and mutant sequence peptide based vaccines. J Exp Med 1996;183:1357-1365.
120. Mayordomo JI, Zorina T, Storkus WJ, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo A, Lotze MT: Bone marrow derived DC's pulsed with tumor peptides effectively treat established murine tumors. Nature Med 1995;1:1297-1302.
121. Parkhurst MR, Salgaller M, Southwood S, Robbins P, Sette A, Rosenberg SA, Kawakami Y: Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A0201 binding residues. J Immunol 1996;157:2539-2548.
122. Kang X, Robbins PF, Fitzgerald EB, Wang RF, Rosenberg SA, Kawakami Y: Induction of melanoma reactive T-cells by stimulator cells expressing melanoma epitope-MHC class I fusion proteins. Cancer Res 1997;57:202-205.
123. Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM: Peptide vaccinination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 1996; 93:7855-7860.
124. Chamberlain RS, Carroll MW, Bronte V, Hwu P, Warren S, Yang JC, Nishimura M, Moss B, Rosenberg SA, Restifo NP: Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res 1996; 56:2832-2836.
125. Warnier C, Duffour MT, Uyttehove C, Gajewski TF, Lurquin C, Haddada H, Perricaudet M, Boon T: Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int J Cancer 1996;67:303-310.
126. Irvine K, Rao J, Rosenberg S, Restifo N: Cytokine enhancement of DNA immunization leads to treatment of established pulmonary metastases. J Immunol 1996; 156:238-245.
127. Reeves ME, Royal RE, Lam JS, Rosenberg SA, Hwu P: Retroviral transduction of human dendritic cells with a tumor associated antigen gene. Cancer Res 1996;56: 5672-5677.
128. Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, Restifo NP: IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 1995;154:5282-5292.
129. Rao JB, Chamberlain RS, Bronte V, Carroll MW, Irvine KR, Moss B, Rosenberg SA, Restifo NP: IL12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol 1996;156:3357-3365.
130. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
131. Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, Simonis TB, Duray PH, Herlyn M, Kawakami Y, Rosenberg SA: Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother 1996:19: 192-205.
132. Ferrone S, Marincola FM: Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance, Immunol Today 1995;10:487-494.
133. Maeurer M, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, Robbins P, Parmiani G, Storkus W, Lotze M: Tumor escape from immune recognition: Lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immmunodominant MART-1/ Melan-A antigen. J Clin Invest 1996;98:1633-1641.
134. Topalian SL, Kasid A, Rosenberg SA: Immunoselection of a human melanoma resistant to specificlysis by autologous tumor-infiltrating lymphocytes: possible mechanisms for immunotherapeutic failures. J Immunol 1990; 144:4487-4495.
135. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yanelli JR, Rosenberg SA: Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996; 88:100-108.
136. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC: Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992;258: 1795-1798.
137. Hahne M, Rimoldi D, Schroter P, Romero P, Schreier M, French LE, Schneider P, Bomand A, Fontana A, Lienard D, Cerottini JC, Tschopp J: Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science 1996;274:1363-1366.